ash 2019: melflufen dex — horizon trial update | dr. agne paner
Published 4 years ago • 729 plays • Length 3:23Download video MP4
Download video MP3
Similar videos
-
0:59
dr. paner on horizon trial in multiple myeloma
-
1:37
ash 2019: the lyra study update | dr. robert rifkin
-
3:43
agne paner, ash 2019: new approaches in the treatment of relapsed/refractory plasma cell dyscrasias
-
3:35
dreamm trial update - blenrep in myeloma trials | natalie callander, md | ash 2021
-
2:55
ash 2019: the optimum trial | dr. martin kaiser
-
14:04
2016 national conference: dr sebag- daratumumab for the treatment of myeloma
-
1:15:00
smoldering myeloma: what we know and where we're going
-
2:38
how close is a cure for multiple myeloma?
-
3:47
ash 2019: ixazomib as maintenance therapy results | dr. ravi vij
-
1:38
ash 2018: dara/rev/dex/velcade for newly diagnosed multiple myeloma patients
-
7:59
real world evidence for myeloma patients on (ird) ixaxomib/lenalidomide/dex | ash 2021
-
2:01
ash 2019: high-risk smoldering myeloma treatment research | dr. irene ghobrial
-
3:13
horizon: melflufen plus dexamethasone shows efficacy in r/r myeloma
-
5:07
a new horizon: melflufen for r/r multiple myeloma
-
4:19
ash 2019: new drugs targeting bcma — immunotherapy for myeloma | dr. gareth morgan
-
5:39
majestec-2 trial | emma searle, mbchb ma mrcp frcpath phd | ash 2022
-
1:03:36
know your myeloma therapy: melflufen (relapsed/refractory myeloma patients)
-
3:58
ash 2019 pre-clinical updates
-
2:27
ash 2018: dara velcade dex with or without venetoclax
-
4:15
ash 2018: blood monitoring